Actively Recruiting
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-08
60
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of ASL in brain metastases suspected of progression/radionecrosis after GK treatment
CONDITIONS
Official Title
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Brain metastasis from histologically proven tumor
- GK treatment within 4 month prior to the inclusion
- Lesions suspected of progression or radionecrosis with at least 25% size progression
- Lesion size with gadolinium enhanced part of the tumor of 1 cm or larger
You will not qualify if you...
- Pregnancy
- Medical history of primitive brain tumor
- MRI incompatibility or history of contrast agent allergy
- Claustrophobia
- Patient unable to consent
- Epilepsy or recent stroke
- Participation in other studies
- No health care insurance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de neuroradiologie, hôpital Pitié Salpêtrière
Paris, France, 75013
Actively Recruiting
Research Team
N
Natalia SHOR, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here